

Bruton's tyrosine kinase (Btk) associates with protein kinase C μ

Franz-Josef Johannes^{a,b,*}, Angelika Hausser^a, Peter Storz^a, Lars Truckenmüller^a, Gisela Link^a, Toshiaki Kawakami^c, Klaus Pfizenmaier^a

^a*Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany*

^b*Fraunhofer Institut für Grenzflächen- und Bioverfahrenstechnik, Nobelstraße 12; 70569 Stuttgart, Germany*

^c*Division of Allergy, La Jolla Institute for Allergy and Immunology, 10335 Science Center Drive, San Diego, CA 92121, USA*

Received 23 August 1999; received in revised form 15 October 1999

Abstract Bruton's tyrosine kinase (Btk) is considered an essential signal transducer in B-cells. Mutational defects are associated with a severe immunodeficiency syndrome, X-chromosome linked agammaglobulinemia (XLA). Here we show by coimmunoprecipitation that a member of the protein kinase C (PKC) family, PKC μ , is constitutively associated with Btk. Neither antigen receptor (Ig) crosslinking nor stimulation of B-cells with phorbol ester or H₂O₂ affected Btk/PKC μ interaction. GST precipitation analysis revealed association of the Btk pleckstrin/Tec homology domain with PKC μ . Transient overexpression of PKC μ deletion mutants as well as expression of selected PKC μ domains in 293T cells revealed that both the kinase domain and the regulatory C1 region are independently capable of binding to the Btk PH-TH domain. These data show the existence of a PKC μ /Btk complex in vivo and identify two PKC μ domains that participate in Btk interaction.

© 1999 Federation of European Biochemical Societies.

1. Introduction

During antigen receptor induced signal transduction of lymphocytes protein tyrosine kinases of the Src, Syk and Tec family are considered to play essential roles [1,2]. Receptor proximal signals are initiated via src kinase directed activation of Syk and ZAP70 kinases followed by the activation of phosphotyrosine/SH2 domain mediated signal cascades including the phosphatidylinositol second messenger system and serine kinases of the protein kinase C (PKC) family, which fuel several downstream targets finally leading to a proliferative response of T- [1,3] and B-cells [2]. Tec kinases are expressed in T- and B-cells and also in mast cells. Much attention has been focused on one member, Bruton's tyrosine kinase (Btk) [4]. The Btk gene is variously mutated in X-linked immunodeficient mice (xid) or in X-linked agammaglobulinemia patients (XLA) [4,5]. These patients lack circulating B-cells and immunoglobulins and are therefore very vulnerable to infectious diseases [6]. Accordingly, Btk function is considered to be associated with development and activation of B-cells e.g. by controlling the PLC γ mediated intracellular Ca²⁺ signalling [7]. Within B-cell receptor triggered Btk activation, src kinases and PI-3 kinase [8] are implicated. Aside from B-cell specific

functions, Btk has been shown to be involved in Fc ϵ RI induced mast cell degranulation and cytokine production through c-Jun N-terminal kinase (JNK) activation [9,10].

Btk contains a SH2, SH3, a Tec homology (TH) domain and, within the amino terminal region, a pleckstrin homology (PH) domain. This recently identified novel signal module [11] was found to mediate membrane association via lipid binding and, in addition, mediates protein-protein interactions [12]. For Btk, PH domain mediated PIP₃ binding is essential for activation leading to PLC γ tyrosine phosphorylation [8,13]. The importance of the PH domain as a regulator of Btk function was shown by expression of a PH domain mutant which leads to enhanced membrane association of Btk resulting in a transformed phenotype, suggestive of an upregulated Btk function [14].

In the light of these data, studies reporting binding of the PH domain of Btk to the regulatory C1 region of PKC [15,16] are of interest. Binding of PKC has been mapped to the amino terminal region of the PH domain of Btk [16] which is considered to represent the lipid binding domain [17,18]. Both, phosphatidylinositol phosphates and PKC, have been shown to bind with similar affinities [19,16], providing an example that PH domain mediated functions can be regulated by both protein and lipid ligands. For Tec kinases, the physiological function of PKC association appears to be the phosphorylation dependent regulation of Tec kinase activity [20,15], pointing to a regulatory role of PKCs within Tec kinase mediated signalling pathways.

We have recently described a novel PKC isotype, termed PKC μ [21], which, although ubiquitously expressed, shows particularly high expression in thymus and hematopoietic cells [22]. In addition to the conserved kinase- and regulatory domains in common to all PKC isoforms, PKC μ displays structural features like a hydrophobic amino terminal domain, an acidic regulatory domain [23] and a pleckstrin homology domain [11]. First evidence for involvement of PKC μ in diverse cellular functions stems from reports showing enhancement of constitutive transport processes in PKC μ overexpressing epithelial cells [24] and PKC μ activation during antigen receptor mediated signalling in B-cells [25].

In the present study, we provide biochemical evidence that PKC μ is constitutively associated with Btk and show by in vitro binding studies, that both the kinase domain and the regulatory C1 domain of PKC μ interact with Btk.

2. Materials and methods

2.1. Recombinant PKC μ , construction of mutants and cell lines

The production of Sf158 insect cells overexpressing PKC μ has been described previously [26]. A cDNA fragment coding for the Btk pleck-

*Corresponding author. Fax: (49) (711) 685-7484.
E-mail: franz-josef.johannes@po.uni-stuttgart.de

Abbreviations: PKC, protein kinase C; GST, glutathione *S*-transferase; Pdbu, phorbol 12,13-dibutyrate; Btk, Bruton's tyrosine kinase; SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis; xid, X-chromosome linked immunodeficiency; JNK, c-Jun N-terminal kinase

strin homology domain including the TH domain [27] (amino acid 1–174, Btk PH-TH) was amplified introducing an *EcoRI* and an *XhoI* site. The cDNA fragment was cloned in frame with the glutathione *S*-transferase (GST) in pGEX5X-3 and expressed as a bacterial fusion protein. The human B-cell line SKW 6.4 was maintained in RPMI 1640 medium supplemented with 5% FCS. GST fusion proteins were isolated according to the manufacturer's instructions (Pharmacia). In brief, fusion proteins were bound to glutathione sepharose and quantified upon Coomassie staining by densitometric scanning, calibrated against an albumin standard. The PKC μ deletion mutant PKC $\mu_{\Delta 1-340}$ was constructed by deleting the respective cDNA region by restriction enzyme digest, initiating translation at Met-340 as described [28]. PKC $\mu_{\Delta PH}$ and PKC $\mu_{\Delta AD}$ were created using a fusion PCR approach looping out the coding region from K417–G553 (PKC $\mu_{\Delta PH}$) and E336–D391 (PKC $\mu_{\Delta AD}$), respectively. Initial PCR to amplify the 5'-cDNA fragment was carried out with a forward primer annealing at nucleotide position 478 of the PKC μ cDNA and a reverse primer annealing at the 5' and 3'-end of the cDNA region to be looped out. Amplification of the 3'-cDNA fragment was carried out using a reverse primer annealing at nucleotide position 3000 of the PKC μ cDNA creating a *BamHI* site and a forward primer annealing at the 5'- and 3'-end of the cDNA fragment to be looped out. Fusion PCR generated a 2130-bp cDNA fragment for the ΔPH and a 2350-bp cDNA fragment for the ΔAD mutant. PCR fragments were digested with *HindIII* and *BamHI* and used to replace the PKC μ wild-type cDNA fragment cloned in the expression vector pCDNA3 (Invitrogen). The presence of the deletions was verified by dideoxy sequencing of both strands. The PKC μ C1 region covering amino acids 1–327 and the kinase domain (amino acids 550–912) was PCR amplified adding 5'-*EcoRI* and 3'-*XbaI* restriction sites and cloned in pCDNA3. The construction of the kinase dead PKC μ mutant (K612W) has been described previously [29]. This mutant can be weakly immunoprecipitated by the carboxyl terminal PKC μ antibody. The R28P mutant of the Btk PH domain cDNA (Btk-mut) was constructed by PCR based mutagenesis exchanging Arg-28 (CGC) to Pro-28 (CCC) according to the manufacturer's instructions (Quick change site directed mutagenesis, Stratagene) and was verified by dideoxy sequencing. FLAG tagged JNK cloned in pCDNA3 was used as a control for specificity of GST Btk PH-TH domain precipitation.

2.2. Immunoprecipitation by antibodies and GST fusion protein precipitation of PKC μ

Cells were either left untreated or stimulated with phorbol ester (100 nM, 10 min), Anti-IgG or H₂O₂/pervanadate as described [30] before lysis at 4°C in lysis buffer (20 mM Tris pH 7.4, 5 mM MgCl₂, 1% Triton X-100, 1 mM Na-orthovanadate, 150 mM NaCl, 10 µg/ml leupeptin, 0.5 mM PMSF, 1 mM NaF, 1 mM nitrophenylphosphate) by incubating 30 min. After centrifugation of cell debris (15 min, 15000 rpm) GST precipitation was done in 1 ml lysate portions (500000 Sf 158 cells or 50×10⁶ Jurkat cells) by incubation with the indicated amounts of GST fusion proteins coupled to glutathione sepharose for 90 min at 4°C. For immunoprecipitation a PKC μ antibody directed against carboxyl terminal epitopes and a Btk rabbit antibody directed against amino terminal epitopes (both from Santa Cruz Biotechnology) were used. Immunocomplexes were harvested by incubation with protein G sepharose (Pharmacia, 30 µl/5×10⁷ cell equivalents) for 30 min at 4°C. Immuno- or GST-complexes were washed three times in lysis buffer and subjected to SDS-PAGE followed by transfer to a nitrocellulose membrane. Western blot detection of PKC μ and Btk was performed using either Btk or PKC μ antibodies as recommended by the manufacturer. GST was detected using an anti-GST antibody (Pharmacia). Western blots were stained using an alkaline phosphatase based detection system according to standard conditions.

2.3. Generation of PKC μ specific antibodies

Purified PKC μ , produced from Sf158 insect cells was used to immunize Balb/c mice. Using PKC μ specific immune serum and several PKC μ domain GST fusion proteins the antibody binding epitope could be mapped within the amino terminal region (amino acids 1–327). This mouse antiserum was used to immunoprecipitate the amino terminal expressed PKC μ domain in 293T cells.

2.4. Transfection of 293T cells

Two million cells were seeded per 90-mm-diameter dish in 10 ml

RPMI supplemented with 5% FCS and transfected with 10 µg of DNA and 50 µl Superfect reagent (Qiagen) according to the manufacturer's protocol. Cells were harvested 40 h upon transfection and analyzed by GST pull down assays or immunoprecipitation as described above.

3. Results and discussion

3.1. Btk associates with PKC μ

Btk is expressed in B-cells and involved in early B-cell receptor initiated signalling pathways [31] in a similar way as the tyrosine kinase Syk which has been reported to associate with PKC μ [25]. Therefore, we analyzed potential in vivo association of PKC μ and Btk by coimmunoprecipitation from B-cells. SKW 6.4 B-cells were shown by Western blot analyses to express PKC μ and Btk in detectable amounts (data not shown). Btk was immunoprecipitated from phorbol ester stimulated or untreated SKW 6.4 cells using a rabbit antibody directed against amino terminal epitopes (Fig. 1A, lanes 1,2). In Btk immunoprecipitates, PKC μ was hardly detectable. However, Btk was readily detectable in PKC μ immunoprecipitates from both, phorbol 12,13-dibutyrate (Pdbu) stimulated and non-stimulated SKW 6.4 cells using two different, PKC μ specific antibodies of rabbit and mouse origin, directed against carboxyl terminal and amino terminal regions, respectively (Fig. 1A, lanes 3,4,8,9). A previously noted characteristic of the carboxyl terminal PKC μ specific antibody is its weaker binding to Pdbu activated, compared to non-activated PKC μ [22], leading therefore to a reduced PKC μ detection and a slightly reduced Btk precipitation efficacy (Fig. 1A, lane 3 vs. 4). SKW 6.4 B-cells were either activated with anti-IgG or the substitute stimulus, H₂O₂-pervanadate [30], resulting in PKC μ activation (data not shown) to monitor potential changes in Btk association. However, no changes in Btk association were found (Fig. 1A, lanes 5,6). As a negative control, PKC μ immunoprecipitates from Molt 4 cells, which do not express detectable amounts of Btk (data not shown), but high amounts of PKC μ , were analyzed. As shown in Fig. 1A (lane 7), only the expected PKC μ specific band was detectable, verifying the specificity of immunoprecipitation and Western blot reagents.

The PH domain of Btk has been reported to mediate association with PKCs in vitro and in vivo [15,16]. Further on it has been shown that the region close to the PH domain, the TH domain (Tec homology) [27], is essential for Btk structure and function [32]. In order to identify whether this region is critical for the Btk interaction with PKC μ , we analyzed recombinant PKC μ for potential Btk PH-TH domain association. The Btk PH-TH domain was expressed as bacterial GST fusion protein (see Section 2). Immobilized Btk PH-TH domain GST fusion protein was used to precipitate PKC μ expressed in Sf158 cells. As shown in Fig. 1B, PKC μ can be detected by immunoblot analysis (upper panel) in precipitates of GST fusion proteins with the Btk PH-TH domain. Using different amounts of GST Btk PH-TH domain fusion protein, PKC μ can be readily detected with 1 µg, showing best detection using 10 µg of Btk PH-TH domain GST fusion proteins (Fig. 1B). The specificity of PKC μ binding to Btk PH-TH domain was shown by pull down analysis of high amounts of bacterial GST proteins producing no specific PKC μ immunoreactive signal (Fig. 1B, right lanes). Mutation of arginine-28 in Btk either to histidine, proline or cysteine has been




Fig. 1. Btk is associated with PKCμ. A: Btk coimmunoprecipitates with PKCμ. Shown are immunoprecipitates from lysates of 40×10^6 SKW 6.4 (lanes 1–6,8,9) or Molt 4 (lane 7) cells. Btk was immunoprecipitated using an amino terminal rabbit antibody. PKCμ was immunoprecipitated using a rabbit antibody raised against carboxyl terminal epitopes (lanes 3–7) or a mouse antiserum against amino terminal PKCμ regions (lanes 8,9). Detection was carried out with the carboxyl terminal antiserum. Cells were either left unstimulated or stimulated with phorbol ester (PdBu), anti-IgG or H₂O₂ as described in Section 2. B: The Btk PH-TH domain associates with recombinant PKCμ. PKCμ expressed in Sf158 cells was precipitated with the indicated amounts of Btk/Btk-mut GST PH-TH domain fusion proteins or with GST protein as a control. Bound PKCμ was detected by immunoblot analysis using a PKCμ antiserum and an alkaline phosphatase coupled secondary antibody. GST (26 kDa) or GST fusion proteins (40 kDa) were visualized using a goat anti-GST antibody.

reported to be associated with the XLA or xid phenotype in humans or mice [5], affecting PKC interaction [15]. Therefore we tested whether this mutation would affect PKCμ binding. A GST Btk PH-TH domain fusion protein carrying the R28P mutation indeed resulted in a decreased PKCμ pull down efficacy (Figs. 1B and 3B). These findings are consistent with previous observations [15] and point to a potential role of PKCμ in Btk mediated signalling pathways affected in the immunodeficiency XLA phenotype. Using GST PH-TH domain fusion proteins of Btk, endogenous PKCμ was similarly precipitated from extracts of phorbol ester stimulated or non-stimulated SKW 6.4 cells (data not shown).

3.2. The C1 region or the kinase domain of PKCμ are sufficient to mediate Btk PH-TH domain binding

The cysteine fingers in the C1 region of PKCs have been shown to represent the binding site for lipid second messengers as well as for regulatory proteins affecting protein kinase activity [33,34]. The PH domain of Btk has been reported to bind to the regulatory C1 domain of PKCε [16]. Although considerably different in primary structure, the C1 region of PKCμ shares the typical consensus sequence of zinc fingers responsible for phorbol ester or second messenger binding. We therefore used several PKCμ deletion mutants lacking the C1 region and other predicted functional domains to

map the binding site of the Btk PH-TH domain. Fig. 2A displays the location of functional PKCμ domains.

Transfection of the PKCμ mutant PKCμ Δ 1–340 lacking the C1 region [35] in 293T cells resulted in the expression of an approximately 70-kDa PKCμ variant (wild-type 115 kDa) as shown by Western blot analysis (Fig. 2B). Two further deletions of PKCμ domains considered to be involved in PKCμ regulation were constructed: deletion of the predicted PKCμ PH domain [11] (K417–G553, PKCμ Δ PH) and of an acidic region (E336–D391, PKCμ Δ AD for acidic domain), the latter of which is considered to participate in a phorbol ester independent activation [23], results in expression of 90-kDa or 100-kDa PKCμ mutants (Fig. 2B). A point mutation (K612W), creating a kinase deficient mutant, was also employed.

Btk PH-TH domain GST fusion proteins were used to precipitate PKCμ mutants from lysates of 293T cells transiently transfected with the respective expression constructs. As shown in Fig. 2C, PKCμ could be readily detected in all Btk precipitation analyses from 293T cells expressing wild-type PKCμ and PKCμ mutants. In contrast to binding of 14-3-3 proteins to the regulatory region [35], kinase activity




Fig. 2. Mapping of Btk binding domains in PKCμ. A: Schematic view of the known functional domains of PKCμ. B: Expression of PKCμ mutants. 293T cells were transfected with the indicated PKCμ mutants and detected by Western blot analysis using a carboxyl terminal rabbit antibody. C: Determination of the Btk PH-TH binding domain in PKCμ. A GST Btk PH-TH domain fusion protein was used to precipitate wild-type and the truncated PKCμ proteins upon transient overexpression in 293T cells. As a control FLAG-tagged JNK was transfected and analyzed in parallel. Expression was monitored using an anti-FLAG monoclonal antibody.




Fig. 3. BTK PH-TH GST fusion proteins bind to the kinase domain and the regulatory C1 region of PKC μ . A: Expression of PKC μ domains. The PKC μ kinase domain and the amino terminal region were transiently expressed in 293T cells. The kinase domain was detected using a carboxyl terminal antibody, the C1 domain with a polyclonal mouse antiserum. B: GST Btk PH-TH fusion proteins bind specific to the kinase domain and the regulatory region of PKC μ . Shown are precipitation analyses using the wild-type Btk PH-TH GST domain fusion protein (PH) or Btk carrying the R28P mutation (PH-mut). PKC μ was detected using a mix of the domain specific antibodies. As a control for specificity GST precipitations were included (data not shown).

was not essential to precipitate PKC μ by GST Btk PH-TH domain fusion proteins. The kinase deficient PKC μ mutant PKC μ _{K612W} was precipitated with similar efficacy like wild-type PKC μ (Fig. 2C, lower panel). FLAG-tagged JNK, which was also expressed at a significant level, was not precipitated and served as a control of specificity of GST Btk PH-TH pull down assay (Fig. 2B and C, right lanes).

In contrast to previous data identifying the C1 domain of phorbol ester responsive PKCs as the binding domain of the Btk PH domain [16], our findings using GST PH-TH domain fusion proteins point to a different association mode between Btk and PKC μ , involving its kinase domain too. To determine in detail which region of PKC μ mediates Btk PH-TH domain binding, the PKC μ C1 domain covering amino acids 1–327 including the cysteine rich zinc finger like structure and the kinase domain were expressed in 293T cells and analyzed for potential Btk binding by precipitation assays (Fig. 3A). As shown in Fig. 3B, the C1 region as well as the kinase domain of PKC μ could be precipitated by Btk GST PH-TH domain fusion proteins. No specific band was detectable by Western blot analysis in GST Btk TH-PH precipitates from 293T cells transfected with vector without insert (Fig. 3B, left lanes) or with the Syk tyrosine kinase as an additional control for specificity (data not shown). These data as well as the finding that JNK could not be precipitated by GST Btk-mut PH-TH fusion proteins (Fig. 2C) point to a specific interaction of PKC μ domains with Btk. The R28P mutation known to affect Btk function and binding to PKCs was analyzed for potential inhibition of PKC μ association. As shown in Fig. 3B, the R28P GST Btk PH-TH fusion protein did not significantly affect PKC μ kinase domain binding whereas the R28P fusion protein strongly reduces the precipitation efficacy of the PKC μ C1 domain (Fig. 3B, right lane). According to these

data two independent binding sites of the Btk PH-TH domain can be postulated in PKC μ . These findings explain the partial inhibition of GST Btk-mut PH-TH domain binding shown in Fig. 1B, because only one of two binding sites is affected. The presence of two independent Btk PH-TH domain binding sites provides an explanation for the finding that in vitro precipitation of PKC μ by GST Btk PH-TH is only weakly competed by Pdbu containing phosphatidylserine micelles (data not shown), similarly as shown for other PKCs [16].

Although Btk is physically associated with PKC μ , the precise molecular mechanism of Btk PH-TH domain interaction with PKC μ and the physiological relevance of this interaction is currently unknown. cPKC mediated phosphorylation of Btk in vitro leads to reduced tyrosine autophosphorylation [15] and therefore has been suggested to negatively regulate Btk activity. Immunoprecipitates of Btk as well as GST PH-TH domain fusion proteins are no substrates for in vitro phosphorylation by recombinant PKC μ (F.J.J., unpublished observations) suggesting that PKC μ alone is not sufficient for effective serine phosphorylation of Btk. Vice versa, PKC μ is not considered as a substrate for Btk, as there is no significant tyrosine phosphorylation upon cellular stimulation (F.J.J., unpublished observations). As our data indicate no direct in vitro phosphorylation of either PKC μ or Btk, association mediated regulation of PKC μ and/or Btk kinase activity in vivo might be dependent on the presence of additional, currently unknown factors. Alternatively, PKC μ might serve as a scaffold protein generating a Btk activating signal complex. In favor of this hypothesis are the findings that the C1 domain of PKC μ serves as binding region for phosphatidylinositol 4-kinase and a phosphatidylinositol 4-phosphate 5-kinase [28] producing phosphatidylinositol phosphates which are involved in Btk membrane translocation which is a prerequisite for activation. Such a model would predict that the amino terminal region of Btk mediates PKC μ C1 domain association, whereas carboxyl terminal epitopes of the Btk PH-TH domain are responsible for constitutive association with the PKC μ kinase domain.

In B-lymphocytes, PKC μ is associated with the initial B-cell receptor signalling complex together with PLC γ 1/2 and the tyrosine kinase Syk upon IgM stimulation [25]. As Btk is essential for PLC γ 2 activation [36] a participation of Syk, Btk and PKC μ in the regulation of PLC γ triggered signalling pathways is conceivable. The role of PKC μ in the cellular signalling complex as a potential negative regulator of PLC γ [25] or regulator of Btk will be a subject to further research activities.

The demonstration of in vitro association of PKC μ with Btk points to a role in receptor proximal signalling events of lymphocyte antigen receptors. As, in addition to PKC μ , several other PKC isotypes also associate with Btk [16], they might be components of a partially redundant signalling system. This is underlined by the in vivo phenotype of the PKC β knock-out mouse, showing a similar, but milder immunodeficiency syndrome as compared to the Btk defective xid mouse [6,37]. It is therefore possible that the defects in signal transduction pathways involving PKC β are compensated in the PKC β knock out mouse by other lymphocyte expressed PKC isotypes, probably including PKC μ .

Acknowledgements: This work was supported by the Deutsche Forschungsgemeinschaft, Grant no. Jo227/4-3.

References

- [1] Qian, D. and Weiss, A. (1997) *Curr. Opin. Cell Biol.* 9, 205–212.
- [2] Kurosaki, T. (1997) *Curr. Opin. Immunol.* 9, 309–318.
- [3] Keenan, C., Long, A. and Kelleher, D. (1997) *Biochim. Biophys. Acta* 1358, 113–126.
- [4] Tsukada, S., Saffran, D.C., Rawlings, D.J., Parolini, O., Allen, R.C., Klisak, I., Sparkes, R.S., Kubagawa, H., Mohandas, T. and Quan, S. et al. (1993) *Cell* 72, 279–290.
- [5] Vihinen, M., Brandau, O., Branden, L.J., Kwan, S.P., Lappalainen, I., Lester, T., Noordzij, J.G., Ochs, H.D., Ollila, J., Pienaar, S.M., Riikonen, P., Saha, B.K. and Smith, C.I.E. (1998) *Nucleic Acids Res.* 26, 242–247.
- [6] Sideras, P. and Smith, C.I. (1995) *Adv. Immunol.* 59, 135–223.
- [7] Fluckiger, A.C., Li, Z., Kato, R.M., Wahl, M.I., Ochs, H.D., Longnecker, R., Kinet, J.P., Witte, O.N., Scharenberg, A.M. and Rawlings, D.J. (1993) *EMBO J.* 17, 1973–1985.
- [8] Li, Z., Wahl, M.I., Eguinoa, A., Stephens, L.R., Hawkins, P.T. and Witte, O.N. (1997) *Proc. Natl. Acad. Sci. USA* 94, 13820–13825.
- [9] Hata, D., Kawakami, Y., Inagaki, N., Lantz, C.S., Kitamura, T., Khan, W.N., Maeda-Yamamoto, M., Miura, T., Han, W., Hartman, S.E., Yao, L., Nagai, H., Goldfeld, A.E., Alt, F.W., Galli, S.J., Witte, O.N. and Kawakami, T. (1998) *J. Exp. Med.* 187, 1235–1247.
- [10] Kawakami, Y., Miura, T., Bissonnette, R., Hata, D., Khan, W.N., Kitamura, T., Maeda-Yamamoto, M., Hartman, S.E., Yao, L., Alt, F.W. and Kawakami, T. (1997) *Proc. Natl. Acad. Sci. USA* 94, 3938–3942.
- [11] Gibson, T.J., Hyvonen, M., Musacchio, A., Saraste, M. and Birney, E. (1994) *Trends Biochem. Sci.* 19, 349–353.
- [12] Yao, L., Janmey, P., Frigeri, L.G., Han, W., Fujita, J., Kawakami, Y., Apgar, J.R. and Kawakami, T. (1999) *J. Biol. Chem.* 274, 19752–19761.
- [13] Scharenberg, A.M., El-Hillal, O., Fruman, D.A., Beitz, L.O., Li, Z., Lin, S., Gout, I., Cantley, L.C., Rawlings, D.J. and Kinet, J.P. (1998) *EMBO J.* 17, 1961–1972.
- [14] Li, T., Rawlings, D.J., Park, H., Kato, R.M., Witte, O.N. and Satterthwaite, A.B. (1997) *Oncogene* 15, 1375–1383.
- [15] Yao, L., Kawakami, Y. and Kawakami, T. (1994) *Proc. Natl. Acad. Sci. USA* 91, 9175–9179.
- [16] Yao, L., Suzuki, H., Ozawa, K., Deng, J., Lehel, C., Fukamachi, H., Anderson, W.B., Kawakami, Y. and Kawakami, T. (1997) *J. Biol. Chem.* 272, 13033–13039.
- [17] Hyvonen, M., Macias, M.J., Nilges, M., Oschkinat, H., Saraste, M. and Wilmanns, M. (1995) *EMBO J.* 14, 4676–4685.
- [18] Harlan, J.E., Hajduk, P.J., Yoon, H.S. and Fesik, S.W. (1994) *Nature* 371, 168–170.
- [19] Lemmon, M.A., Ferguson, K.M., O'Brien, R., Sigler, P.B. and Schlessinger, J. (1995) *Proc. Natl. Acad. Sci. USA* 92, 10472–10476.
- [20] Kawakami, Y., Yao, L., Tashiro, M., Gibson, S., Mills, G.B. and Kawakami, T. (1995) *J. Immunol.* 155, 3556–3562.
- [21] Johannes, F.J., Prestle, J., Eis, S., Oberhagemann, P. and Pfizenmaier, K. (1994) *J. Biol. Chem.* 269, 6140–6148.
- [22] Rennecke, J., Johannes, F.J., Richter, K.H., Kittstein, W., Marks, F. and Gschwendt, M. (1996) *Eur. J. Biochem.* 242, 428–432.
- [23] Gschwendt, M., Johannes, F.J., Kittstein, W. and Marks, F. (1997) *J. Biol. Chem.* 272, 20742–20746.
- [24] Prestle, J., Pfizenmaier, K., Brenner, J. and Johannes, F.J. (1996) *J. Cell Biol.* 134, 1401–1410.
- [25] Sidorenko, S.P., Law, C.L., Klaus, S.J., Chandran, K.A., Takata, M., Kurosaki, T. and Clark, E.A. (1996) *Immunity* 5, 353–363.
- [26] Dieterich, S., Herget, T., Link, G., Bottinger, H., Pfizenmaier, K. and Johannes, F.J. (1996) *FEBS Lett.* 381, 183–187.
- [27] Vihinen, M., Nilsson, L. and Smith, C.I. (1994) *FEBS Lett.* 350, 263–265.
- [28] Nishikawa, K., Toker, A., Wong, K., Marignani, P.A., Johannes, F.J. and Cantley, L.C. (1998) *J. Biol. Chem.* 273, 23126–23133.
- [29] Johannes, F.J., Horn, J., Link, G., Haas, E., Siemienski, K., Wajant, H. and Pfizenmaier, K. (1998) *Eur. J. Biochem.* 257, 47–54.
- [30] Wienands, J., Larbolette, O. and Reth, M. (1996) *Proc. Natl. Acad. Sci. USA* 93, 7865–7870.
- [31] Kawakami, Y., Kitaura, J., Hata, D., Yao, L. and Kawakami, T. (1999) *J. Leukoc. Biol.* 65, 286–290.
- [32] Hyvonen, M. and Saraste, M. (1997) *EMBO J.* 16, 3396–3404.
- [33] Diaz-Meco, M.T., Municio, M.M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L. and Moscat, J. (1996) *Cell* 86, 777–886.
- [34] Diaz-Meco, M.T., Municio, M.M., Sanchez, P., Lozano, J. and Moscat, J. (1996) *Mol. Cell Biol.* 16, 105–114.
- [35] Hausser, A., Storz, P., Link, G., Stoll, H., Liu, Y.C., Altman, A., Pfizenmaier, K. and Johannes, F.J. (1999) *J. Biol. Chem.* 274, 9258–9264.
- [36] Takata, M. and Kurosaki, T. (1996) *J. Exp. Med.* 184, 31–40.
- [37] Leitges, M., Schmedt, C., Guinamard, R., Davoust, J., Schaal, S., Stabel, S. and Tarakhovsky, A. (1996) *Science* 273, 788–791.